Zura Bio (ZURA) Stock Price, News & Analysis

Company Overview

Zura Bio Limited (NASDAQ: ZURA) is a clinical-stage biotechnology company focused on developing medicines for chronic inflammatory and immune-mediated diseases. The company is advancing therapies designed to address conditions with significant unmet medical needs, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and inflammatory bowel disease.

Zura Bio’s pipeline includes ZB-106, an investigational inhibitor of interleukin-17A and interleukin-17F being evaluated in inflammatory diseases, and ZB-880, an investigational therapy targeting TL1A, a cytokine associated with intestinal inflammation. These candidates are being studied through clinical development programs rather than marketed as approved products.

The company was formed in 2022 and became a publicly traded business in 2023 through a business combination with JATT Acquisition Corp. Zura Bio conducts development activities and clinical research through international programs. As a clinical-stage company, its operations are centered on research, clinical trials and regulatory preparation, with no commercial product portfolio described here.

Key Stats

• Today's Range: $4.16 to $4.55
• 50-Day Range: $4.33 to $6.32
• 52-Week Range: $2.01 to $7.44
• Volume: 2.06 million shs
• Average Volume: 1.44 million shs
• Market Capitalization: $414.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Moderate Buy

Zura Bio Stock Analysis - MarketRank™

Zura Bio scored higher than 54% of companies evaluated by MarketBeat, and ranked 365th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zura Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Zura Bio has a consensus price target of $17.00, representing about 292.6% upside from its current price of $4.33.

Amount of Analyst Coverage

Zura Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Zura Bio are expected to grow in the coming year, from ($0.81) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zura Bio is -3.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zura Bio is -3.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zura Bio has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.22% of the float of Zura Bio has been sold short.

Short Interest Ratio / Days to Cover

Zura Bio has a short interest ratio ("days to cover") of 5.81.

Change versus previous month

Short interest in Zura Bio has recently decreased by 2.99%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zura Bio does not currently pay a dividend.

Dividend Growth

Zura Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Sentiment

Zura Bio has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Zura Bio this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for ZURA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Zura Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zura Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.37% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZURA
• CIK: 1855644
• Web: www.zurabio.com
• Phone: 858-247-0520
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Zura Bio: $17.00
• High Price Target: $22.00
• Low Price Target: $11.00
• Potential Upside/Downside: +292.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$99.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.13%
• Return on Assets: -50.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.90
• Quick Ratio: 12.90

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.38 per share
• Price / Book: 3.14

Miscellaneous

• Outstanding Shares: 95,830,000
• Free Float: 83,975,000
• Market Cap: $414.94 million
• Optionable: Optionable
• Beta: -0.02